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patients with Ewing's sarcoma and in 4 of 10 patients with adrenocortical carcinoma. PD data suggest that cixutumumab alone or combined with temsirolimus increased plasma IGF-1 and IGFBP3. FDG-PET/CT showed the odds of achieving stable disease decreased by 58% (P =0.1213) with a one-unit increase in absolute change of SUV from baseline to Day 3.
Conclusions:
Temsirolimus combined with cixutumumab was well tolerated. We are currently enrolling expansion cohorts at the MTD for Ewing's sarcoma and adrenocortical carcinoma. 
INTRODUCTION
The PI3K/AKT/mTOR pathway is normally regulated by upstream receptor tyrosine kinases, particularly the insulin receptor and type 1 insulin-like growth factor receptor (IGF-1R) 1 . Recent studies in in vitro and in vivo models as well as using tumor biopsies from patients have demonstrated that treatment with mTOR inhibitors leads to upregulation of AKT phosphorylation in tumors, which may antagonize the antiproliferative effects of mTOR inhibition 2, 3 . Several studies have shown that mTOR inhibitors mediate AKT activation through an IGF-1R-dependent mechanism and that IGF-1R inhibitors may abrogate or reduce AKT phosphorylation induced by mTOR inhibitors [2] [3] [4] . AKT activation is related to the escape/resistance mechanism of mTOR inhibitors, but combination studies with rapamycin and IGF-1R inhibitors suggest additive antitumor effects compared to treatment with single agents alone. 5 Thus, combining an mTOR inhibitor and IGF-1R inhibitor may be an appropriate strategy to enhance mTOR-targeted anticancer therapy. Furthermore, as mTOR is involved in signal transduction downstream of IGF-1R, the combination may also potentially enhance the activity of IGF-1R inhibitors.
We report the results of the first Phase I study that combines an mTOR inhibitor (temsirolimus; CCI-779) and an IGF-1R monoclonal antibody (cixutumumab; IMC-A12) to assess safety and tolerability as primary objectives and to evaluate biologic effects and assess tumor metabolism and clinical tumor response as secondary objectives. 
PATIENTS AND METHODS

Eligibility Criteria
Eligible patients had advanced or metastatic, histologically proven malignant tumors and patients enrolled in the maximum-tolerated dose (MTD) expansion cohort must have disease that is accessible to biopsy. Further requirements were age 16 years or older, ECOG performance status of 0 or 1 and life expectancy of more than 12 weeks. Patients must have absolute neutrophil count ≥ 1500/mL; platelets ≥ 100,000/mL; creatinine ≤ 2X ULN; bilirubin ≤ 1.5 X ULN; AST(SGOT) and/or ALT(SGPT) ≤ 5X ULN. There was no limit to prior numbers of treatment, including IGF-1R inhibitors or mTOR inhibitors. Treatment with radiotherapy (except palliative radiation to control symptoms), endocrine therapy, or chemotherapy must have ceased at least 4 weeks before starting treatment. Patients with well-controlled diabetes and hyperlipidemia were allowed in the dose expansion cohort, but were excluded in the dose escalation portion.
Further patient exclusions were treatment with concurrent strong CYP3A modifiers, major surgery within 4 weeks; significant comorbidity, brain metastases and pregnant or nursing females.
Although biopsies were planned, many could not be completed due to patient refusal, absence of tumor in the sample, financial limitations, and other problems. Together, these precluded drawing a meaningful statistical result from the 10 paired biopsies that were done.
Research. 
Study Design
This study used a standard 3+3 design and patients were enrolled across four dose cohorts as shown in Table 1 . At the MTD (cixutumumab 6 mg/kg intravenously [IV] weekly and temsirolimus 25 mg IV weekly), 21 patients were randomized to three separate treatment arms ( Table 2) : 7 patients received cixutumumab before the combination of both agents (Arm A), 6 patients received temsirolimus before the combination of both agents (Arm B), and 8 patients received the combination of both agents at the onset of the study (Arm C). During Cycle 1 only, FDG-PET/CT scans and tumor biopsies with corresponding blood draws for peripheral blood mononuclear cells [PBMCs] were required for all 21 patients. The rationale for establishing 3 separate treatment arms was to evaluate the biological effect of each drug individually and in combination and to allow comparison of pharmacodynamic endpoints, including FDG-PET changes, after treatment with cixutumumab or temsirolimus alone and in combination. We did not perform pharmacokinetic (PK) evaluation since the published data on monoclonal antibodies such as bevazicumab with chemotherapy or small molecules suggested that antibody (which is cleared by the reticuloendothelial system) does not affect the PK of small molecules or cytotoxic agents. 6 This study was performed according to the principles embodied in the Declaration of Helsinki and after approval by the institutional review boards of both centers that enrolled patients. Informed consent was obtained from all patients enrolled on the study. days or thrombocytopenia associated with active bleeding or requiring platelet transfusion, Grade 3 anemia, Grade 4 neutropenia, and drug-related death. MTD was defined as a dose level below the dose at which more than or equal to 33% (2 out of 6 patients) of the patient population experienced a DLT.
Evaluation of Safety
Adverse events were recorded for patients who received at least one dose of cixutumumab or temsirolimus. Severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. Temperature, blood pressure, and pulse were measured before each infusion. Regular monitoring of hematology, blood chemistry and urinalysis, and physical examinations was also performed. was ≥ 30% reduction in the sum of the longest diameters of the lesions, stable disease (SD) was denoted in patients whose sum of longest diameters was not decreased more than 30% and not increased more than 20%, and progressive disease (PD) was a ≥ 20% increase in the sum of the longest diameters of the lesions.
Evaluation of Efficacy
IGF-1 and IGFBP3 Analysis
Plasma samples were collected at baseline and then before infusion on 
RESULTS
Patient Characteristics
Forty-two patients were enrolled across two study centers (The University of Texas MD Anderson Cancer Center, Houston, TX, and Barbara Ann Karmanos Cancer Institute, Detroit, MI). Patient demographic and clinical characteristics at study entry are summarized in Table 3 . The majority of patients were heavily pretreated, with the median number of prior therapies being 4 (range 1-12). Tumor types included breast cancer (n=9), adrenocortical carcinoma (n=10), Ewing's sarcoma (n=3), desmoplastic small-round-cell tumor (n=3), ovarian cancer (n=2), colorectal cancer (n=2), neuroendocrine cancer (n=2), and one patient each had 11 other tumor types.
Toxicities
DLT occurred in two of six patients enrolled at dose level 4 (cixutumumab 6 mg/kg and temsirolimus 37.5 mg). One patient experienced Grade 4 thrombocytopenia and another patient experienced febrile neutropenia. Because the criteria for MTD were exceeded at dose level 4, dose level 3 (cixutumumab 6 mg/kg and temsirolimus 25 mg) was determined to be the MTD for this combination. This dose cohort was expanded to 29 patients, which was composed of eight patients at the MTD and another 21 patients added to the expansion cohort. Among the 29 patients treated at dose level 3, one patient 
breast cancer, n=1; desmoplastic small-round-cell tumor, n=1; adrenocortical carcinoma, n=4; Ewing's sarcoma, n=2) and one other patient with desmoplastic small-round-cell tumor is currently in his third month of treatment and has achieved SD thus far. The greatest tumor reduction was observed in 2 of 3 patients with Ewing's sarcoma (24% and 27% decrease), one of whom had SD for 8 months, and the other having SD for 14 months. Four of 10 patients with adrenocortical carcinoma achieved SD for 8+ months.
IGF-1 and IGFBP3 Levels
We performed pharmacodynamic evaluation of IGF-1 and IGFBP3 in the After adjusting for a total of 9 multiple comparisons, neither of these two differences in means was statistically significant.
Temsirolimus alone given before the combination (Arm B) did not appear to impact the IGF-1 level until cixutumumab was added. The combination given at the beginning of the treatment caused higher IGF-1 plasma levels than cixutumumab alone, indicative that temsirolimus might enhance the inhibition of IGF-1R. So, time certainly affected mean IGF-1 levels, and drug sequence did also, but only at Days 8 and 15. 
DISCUSSION
Weekly administration of cixutumumab, a fully human IgG1 monoclonal antibody directed against the IGF-1R, combined with temsirolimus, an mTOR inhibitor, was well tolerated. MTD was reached at the dose of cixutumumab 6 mg/kg and temsirolimus 25 mg. Three of 42 patients experienced a DLT, which included Grade 3 mucositis, febrile neutropenia, and Grade 4 thrombocytopenia.
One patient had Grade 4 renal failure and required hemodialysis. However, examination of a kidney biopsy in conjunction with clinical presentation suggested that the patient's renal failure was not related to the study drugs and the patient died from disease progression.
Metabolic complications (hyperglycemia and hyperlipidemia) were the most prevalent. During the dose escalation phase, diabetic and hyperlipidemic patients were excluded, however, they were included during dose expansion if they were well controlled prior to enrollment. We worked closely with an endocrinology collaborator to observe and carefully treat those patients when they developed adverse events. Only two patients (known diabetics) developed Grade 3 hyperglycemia, which was correctable with oral agents and insulin fairly rapidly.
Only two patients developed Grade 3 or 4 hypercholesterolemia or hypertriglyceridemia and, again, with appropriate treatment (statins, fibrates and lifestyle changes), they were correctable. With appropriate oversight, consultations and treatment, associated metabolic toxicities were treatable and major complications were avoided. 
Three patients with Ewing's sarcoma were treated, of whom two had durable SD (lasting 8 and 14+ months). Responses in Ewing's sarcoma have been reported with other IGF-1R antibodies, such as AMG479 and R1507 [8] [9] [10] , suggesting that some patients with this tumor may be particularly sensitive to IGF-1R antagonists, supporting the role of IGF-1R signaling in this malignancy. The lack of a response in all patients with Ewing's sarcoma may reflect alterations in pathways that are not abrogated by IGF-1R inhibition. IGFBP3 is more stable when it forms a complex with IGF-1. Therefore, in the presence of elevated circulating IGF-1, IGFBP3 levels may increase as well. Due to various factors, we were not able to perform a meaningful statistical analysis for immunohistochemical and reverse phase protein array assays.
Although FDG-PET/CT is becoming well established as a means to assess metabolic response of many tumor types and was used in this study, it has limitations in some settings. Specifically, studies in the literature identified a variable correlation between FDG uptake and treatment response to mTOR inhibition. 12, 13 In a study with both animal and human subjects 14 , a poor correlation between FDG uptake and clinical response was observed. The changes in FDG uptake seen in treated subjects were in large part due to direct effects on the AKT activation pathway, rather than on the intrinsic metabolic machinery of the tumor cells. Another possibility is that FDG uptake may depend on the type of malignancy studied 
